Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Ascendis Pharma A (ASND) Receivables - Other (2016 - 2025)

Ascendis Pharma A's Receivables - Other history spans 8 years, with the latest figure at $20.5 million for Q4 2023.

  • For Q4 2023, Receivables - Other rose 56.93% year-over-year to $20.5 million; the TTM value through Dec 2023 reached $20.5 million, up 56.93%, while the annual FY2023 figure was $20.7 million, 52.73% up from the prior year.
  • Receivables - Other for Q4 2023 was $20.5 million at Ascendis Pharma A, up from $13.1 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $23.0 million in Q4 2021 and bottomed at $5.1 million in Q4 2019.
  • The 5-year median for Receivables - Other is $13.1 million (2022), against an average of $14.0 million.
  • The largest annual shift saw Receivables - Other skyrocketed 177.11% in 2021 before it tumbled 43.04% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $5.1 million in 2019, then surged by 62.59% to $8.3 million in 2020, then surged by 177.11% to $23.0 million in 2021, then tumbled by 43.04% to $13.1 million in 2022, then surged by 56.93% to $20.5 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Receivables - Other are $20.5 million (Q4 2023), $13.1 million (Q4 2022), and $23.0 million (Q4 2021).